Biogen Inc (BIIB)

326.73
-2.44(-0.74%)
After Hours
326.25
-0.48(-0.15%)
- Real-time Data
  • Volume:
    942,841
  • Bid/Ask:
    325.40/327.00
  • Day's Range:
    325.40 - 331.45

BIIB Overview

Prev. Close
329.17
Day's Range
325.4-331.45
Revenue
11.7B
Open
326.36
52 wk Range
223.25-468.2
EPS
12.47
Volume
942,841
Market Cap
48.69B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
2,013,446
P/E Ratio
26.21
Beta
0.4
1-Year Change
18.94%
Shares Outstanding
149,033,443
Next Earnings Date
25 Oct 2021
What is your sentiment on Biogen Inc?
or
Market is currently closed. Voting is open during market hours.

Biogen Inc News

Biogen Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellSellStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy

Biogen Inc Company Profile

Biogen Inc Company Profile

Employees
9100

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Read More
  • Hit the jackpot with this one kaching
    0
    • Biib is going to give eps $30.21/share,is good buy for long term.
      0
      • Strong buy, biib upgrade target price to $385..stock will up again on next Monday.
        3
        • Eps 30.21/share, is a good buy..
          0
          • Biib is very good stock, can invest for long term. Share will up soon, eps will given on Feb 03,means you need to hold the stock on around Feb 1st
            0
            • bull...call
              0
              • Why has the stock gone down???
                0
                • where do u see biib on the short run ??!!
                  0
                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.